LSE:AAF News 10 January 2026

January 24, 2026, 10:24 PM EST. Elevance Health (ELV), a major U.S. health benefits provider, has shown mixed stock performance: a 5.7% decline over one year and a 21.2% drop over three years, but a 33.7% gain over five years. Despite a recent share price of $371.06, a Discounted Cash Flow (DCF) model estimates an intrinsic value of about $1,011.50, suggesting the stock trades at a 63.3% discount. The DCF analysis projects free cash flow rising from $3.58 billion last year to $8.98 billion by 2030, signaling potential undervaluation. This valuation discrepancy may reflect investor caution influenced by ongoing healthcare sector debates, particularly around costs and insurer stability. Simply Wall St rates the stock's valuation 5 out of 6, underscoring a complex picture for investors evaluating ELV's future prospects and current pricing.